Trillium Therapeutics Inc. (TRIL) Buy Target $4.59 Sell Target $5.88

Trade Setup

Buy Target $4.59
Sell Target $5.88

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.


© Copyright 2020 Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.